All In Biotech

Drug Trial Radar · NCT04657991

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 257 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

257

Actual

Start

Jan 15, 2021

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Conditions

  • Melanoma

Interventions

  • EncorafenibDrug

    Encorafenib

  • BinimetinibDrug

    Binimetinib

  • PembrolizumabDrug

    Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs)Time frame: First 2 Cycles of Treatment (cycles are 21 days)
  2. Phase 3: Objective Response (OR) by Blinded Independent Central Review (BICR)Time frame: Time from the date of randomization until documented PD, start of subsequent anticancer therapy, or death due to any cause (approximately every 9 weeks).

Locations

151 sites in 27 countries. Site status is shown where the registry gives one.

  • AdventHealth Hematology and Oncology

    Orlando, Florida

  • AdventHealth Orlando Infusion Center

    Orlando, Florida

  • AdventHealth Orlando, Investigational Drug Services

    Orlando, Florida

  • The University of Kansas Clinical Research Center

    Fairway, Kansas

  • The University of Kansas Cancer Center - Overland Park

    Overland Park, Kansas

  • KU Eye Center

    Prairie Village, Kansas

  • The University of Kansas Cancer Center - Investigational Drug Services

    Westwood, Kansas

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Ophthalmic Consultants of Boston Inc (OCB)

    Boston, Massachusetts

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • West Chester Hospital

    West Chester, Ohio

  • Tennessee Oncology, PLLC

    Dickson, Tennessee

  • Tennessee Oncology PLLC

    Franklin, Tennessee

  • Tennessee Oncology PLLC

    Gallatin, Tennessee

  • Tenessee Oncology, PLLC

    Hendersonville, Tennessee

  • Tennessee Oncology PLLC

    Hermitage, Tennessee

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Tennessee Oncology PLLC

    Lebanon, Tennessee

  • Tennessee Oncology PLLC

    Murfreesboro, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Tennessee Oncology, PLLC

    Shelbyville, Tennessee

  • Tennessee Oncology PLLC

    Smyrna, Tennessee

  • Instituto Alexander Fleming

    CABA, Buenos Aires, Argentina

  • Clinica Viedma S. A

    Viedma, Río Negro Province, Argentina

  • Medizinische Universität Graz

    Graz, Austria

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Hospital Sírio-Libanês - Unidade Bela Vista

    São Paulo, Brazil

  • Instituto de Oncologia do Paraná - IOP Matriz Mateus Leme

    Curitiba, Paraná, Brazil

  • Instituto de Oncologia do Paraná - IOP Oncoville

    Curitiba, Paraná, Brazil

  • Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital de Clínicas de Passo Fundo

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Complex Oncology Center - Plovdiv EOOD

    Plovdiv, Bulgaria

  • Medical Center Nadezhda Clinical EOOD

    Sofia, Bulgaria

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.